CYP 2D6 polymorphism: A predictor of susceptibility and response to chemoradiotherapy in head and neck cancer

Journal of Cancer Research and Therapeutics

Volumn 8, Issue 1, 2012, Pages 40-45

  Shukla, Pragya ^a   Gupta, Deepak ^a   Pant, Mohan ^b   Parmar, Devendra ^c  

^a TATA MEMORIAL HOSPITAL   (India)

^b KING GEORGE'S MEDICAL UNIVERSITY   (India)

^c CSIR INDIAN INSTITUTE OF TOXICOLOGY RESEARCH   (India)

Author keywords

CYP2D6; head and neck cancer; polymorphism; responders; tobacco

Indexed keywords

CISPLATIN; CYTOCHROME P450 2D6; GENOMIC DNA;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CIGARETTE SMOKING; CONTROLLED STUDY; DNA ISOLATION; GENE FREQUENCY; GENE INTERACTION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HEAD AND NECK CARCINOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TOBACCO; TREATMENT RESPONSE;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CYTOCHROME P-450 CYP2D6; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROGNOSIS; RISK FACTORS; TREATMENT OUTCOME;

EID: 84860475434     PISSN: 09731482     EISSN: 19984138     Source Type: Journal    
DOI: 10.4103/0973-1482.95172     Document Type: Article

References (30)

1. Do KA, Johnson MM, Doherty DA, Lee JJ, Wu XF, Dong Q, et al. Second primary tumors in patients with upper aerodigestive tract cancers: Joint effects of smoking and alcohol (United States). Cancer Causes Control 2003;14:131-8. (Pubitemid 36539519)
2. Adelstein DJ, Li Y, Adams GL, Wagner H Jr, Kish JA, Ensley JF, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003;21:92-8.
3. Calabrese EJ. Biochemical individuality: The next generation. Regul Toxicol Pharmacol 1996;24:S58-67.
4. Chabot GG. Factors involved in clinical pharmacology variability in oncology (review). Anticancer Res 1994;14:2269-72.
5. Guengerich FP. Characterization of human cytochrome P450 enzyme. FASEB J 1992;6:745-8.
6. Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med 2005;352:2211-21.
7. Slaughter RL, Edwards DJ. Recent advances: The cytochrome P450 enzymes. Ann Pharmacother 1995;29:619-24.
8. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: Pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 2007;116:496-526. (Pubitemid 350116943)
9. Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W. Potential role of pharmacogenomics in reducing adverse drug reactions: A systematic review. JAMA 2001;286:2270-9. (Pubitemid 33063150)
10. Johansson I, Oscarson M, Yue QY, Bertilsson L, Sjöqvist F, Ingelman-Sundberg M. Genetic analysis of the Chinese CYP2D locus. Characterization of variant CYP2D6 genes present in subjects with diminished capability for debrisoquine hydroxylation. Mol Pharmacol 1994;46:452-9. (Pubitemid 24296678)
11. Bernard S, Neville KA, Nguyen AT, Flockhart DA. Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: Clinical implications. Oncologist 2006;11:126-35. (Pubitemid 43261759)
12. Ladona MG, Abildúa RE, Ladero JM, Román JM, Plaza MA, Agúndez JA, et al. CYP 2D6 genotypes in Spanish women with breast cancer. Cancer Lett 1996;99:23-8. (Pubitemid 26030349)
13. Gomes L, Lemos MC, Paiva I, Ribeiro C, Carvalheiro M, Regateiro FJ. CYP 2D6 genetic polymorphisms are associated with susceptibility to pituitary tumors. Acta Med Port 2005;18:339-44. (Pubitemid 43198810)
14. Gajecka M, Rydzanicz M, Jaskula-Sztul R, Kujawski M, Szyfter W, Szyfter K. CYP1A1,CYP2D6, CYP2E1, NAT2, GSTM1 and GSTT1 polymorphisms or their combinations are associated with the increased risk of the laryngeal squamous cell carcinoma. Mutat Res 2005;574:112-23. (Pubitemid 40725973)
15. Abdel-Rahman SZ, Anwar WA, Abdel-Aal WE, Ghoneim MA, Au WW. The CYP2D6 extensive metabolizer genotype is associated with increased risk for bladder cancer. Cancer Lett 1997;119:115-22. (Pubitemid 27464673)
16. Roy B, Sikdar N. Polymorphisms in Drug-metabolizing Genes and Risk of Head and Neck Squamous Cell Carcinoma. Int J Hum Genet 2003;3:99-108.
17. Fandino MQ, Hitt R, Medina PP, Gamarra S, Manso L, Funes HC, et al. DNA-Repair Gene Polymorphisms Predict Favourable Clinical Outcome Among Patients With Advanced Squamous Cell Carcinoma of the Head and Neck Treated With Cisplatin-Based Induction Chemotherapy. J Clin Oncol 2006;24:4333-9. (Pubitemid 46630792)
18. Gurubhagavatula S, Liu G, Park S, Zhou W, Su L, Wain JC, et al. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 2004:22:2594-601. (Pubitemid 41103746)
19. Smith CAD, Moss JE, Gough AC, Spurr NK, Wolf CR. Molecular genetic analysis of the cytochrome P450-debrisoquine hydroxylase locus and association with cancer susceptibility. Environ Health Perspect 1992;98:107-12. (Pubitemid 23061790)
20. Smith TJ, Guo Z, Gonzalez FJ, Guengerich FP, Stoner GD, Yang CS. Metabolism of 4-(methylnitrosamino)-l-(3-pyridyl)-l-butanone in human lung and liver microsomes and cytochromes P-450 expressed in hepatoma cells. Cancer Res 1992;52:1757-63.
21. Sobti RC, Onsory K, Al-Badran AI, Kaur P, Watanabe M, Krishan A, et al. CYP17, SRD5A2, CYP1B1, and CYP2D6 gene polymorphisms with prostate cancer risk in North Indian population. DNA Cell Biol 2006;25:287-94. (Pubitemid 43830442)
22. International Agency for Research on Cancer. Alcohol drinking. IARC monographs on the evaluation of carcinogenic risks to humans. vol 44. Lyon: IARC; 1988.
23. Goshman L, Fish J, Roller K. Pharmacotherapy Perspectives Clinically Significant Cytochrome P450 Drug Interactions. In: Vermeulen L, column editor. Center for Drug Policy. USA: University of Wisconsin Hospital and Clinics.
24. Waxman DJ. Steroid hormones and other physiologic regulators of liver cytochromes P450: Metabolic reactions and regulatory pathways. In: Jefcoate CR, guest editor. Vol. 14. Advances in Molecular and Cell Biology; 1996. p. 341-74.
25. Yadav SS, Ruwali M, Shah PP, Mathur N, Singh RL, Pant MC, et al. Association of poor metabolizers of cytochrome P450 2C19 with head and neck cancer and poor treatment response. Mutat Res 2008;644:31-7.
26. Marion LW, Pankaj B, Ilham C, John LM, David AF, Irving WW. A discordance of the cytochrome P450 2C19 genotype and phenotype in patients with advanced cancer. Br J Clin Pharmacol 2000;49:485-8.
27. Ando Y, Fuse E, Figg WD. Thalidomide metabolism by the CYP2C subfamily. Clin Cancer Res 2002;8:1964-73. (Pubitemid 34633760)
28. Nagasubramanian R, Innocenti F, Ratain MJ. Pharmacogenetics in cancer treatment. Annu Rev Med 2003;54:437-52. (Pubitemid 37386406)
29. Zhou W, Gurubhagavatula S, Liu G, Park S, Neuberg DS, Wain JC, et al. Excision repair cross complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res 2004;10:4939-43. (Pubitemid 39099767)
30. Isla D, Sarries C, Rosell R, Alonso G, Domine M, Taron M, et al. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol 2004;15:1194-203. (Pubitemid 39199306)